The Movement Disorder Society of Australia and New Zealand 2016 Meeting

Exclusive Partners

The 2016 Movement Disorder Society of Australia and New Zealand Meeting organisers wish to thank and acknowledge our Exclusive Partners, without which, the Meeting would not be possible. Thank you for making the trip to Sydney.

The Exclusive Partners of the 2016 Movement Disorders Society of Australia and New Zealand Meeting are:

Allergan, Inc. is a multi-specialty health care company focused on discovering, developing and commercialising innovative pharmaceuticals, biologics and medical devices that help people to live life to its greatest potential - to see more clearly, move more freely, express themselves more fully.

STADA Australia and Britannia Pharmaceuticals are wholly owned subsidiaries of STADA Arzneimittel AG, the German-based company with over 120 years heritage in pharmaceuticals. STADA Australia and Britannia, the Originator of Apomorphine, are now working together to supply apomorphine directly to Australia and New Zealand.

We are committed to supporting patients and healthcare professionals through our team of Hospital Specialist Representatives and Nurse Advisors, and look forward to working closely with you to help deliver the optimal level of care for people with Parkinsons, and directly delivering exciting new developments and improvements in Parkinsons therapy.

AbbVie is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott Laboratories. The company's mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world's most complex and serious diseases. Together with its wholly-owned subsidiary, Pharmacyclics, AbbVie employs more than 28,000 people worldwide and markets medicines in more than 170 countries.

For further information on the company and its people, portfolio and commitments, please visit www.abbvie.com. Follow @abbvie on Twitter or view careers on our Facebook or LinkedIn page.

Ipsen provides specialty medicines and quality services to Healthcare Professional and their patients suffering from debilitating diseases.

At Ipsen, our passion is improving the lives of patients. We do this by working together to build partnerships based on trust and mutual respect with Healthcare Professionals. We deliver tailored solutions through our agility and innovation and we strive to be even better tomorrow than we are today.

Ipsen Pty Ltd is the Australian affiliate of a global R & D focused pharmaceutical company.

Merz is a privately held pharmaceutical company based in Frankfurt, Germany. The company is active in research, development and distribution of innovative products in areas of aesthetic medicine and dermatology as well as in the field of neurologically induced movement disorders. Merz developed Xeomin®, the first botulinum toxin that is free of complex proteins.

The Merz Pharma Group employs 2,754 people worldwide and generated revenue of EUR 1,157.0 million in fiscal year 2014/15.

As a global leader in medical technology, services and solutions, Medtronic improves the health and lives of millions of people each year. We believe our deep clinical, therapeutic and economic expertise can help address the complex challenges - such as rising costs, aging populations, and the burden of chronic disease - faced by families and healthcare systems today. But, we can't do it alone. That's why we're committed to partnering in new ways and developing powerful solutions that deliver better patient outcomes.

Founded in 1949 as a medical repair company, we're now among the world's largest medical technology, services and solutions companies, employing more than 85,000 people worldwide, serving physicians, hospitals and patients in more than 160 countries. Join us in our commitment to take healthcare Further, Together. Learn more at Medtronic.com.au.